why choose us

First received: September 21, 2022

Clinical Trial: VA Aripiprazole vs Esketamine for Treatment Resistant Depression

Study Status: NOT_YET_RECRUITING

Recruit Status: NOT_YET_RECRUITING

Condition: Depressive Disorder, Major

Study Type: INTERVENTIONAL


Official Title: VA Aripiprazole vs. Esketamine for Treatment of Depression VAST-D II

Brief Summary: This is an open-label, parallel-group, randomized clinical trial of up to 6 months treatment of adjunctive intranasal (IN) esketamine (ESK) vs. adjunctive aripiprazole (ARI) in Veterans with unipolar Treatment Resistant Depression (TRD).This study will assess the efficacy, safety, and acceptability of adjunctive IN ESK in comparison to ARI, one of the best studied and most widely used adjunctive therapies for TRD.The primary hypothesis is that participants receiving adjunctive IN ESK will be significantly more…

Read more